The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

We recently compiled a list of the 8 Best Humane Stocks to Invest in Now. In this article, we are going to take a look at ...

Gilead Sciences GILD +2.54% Get Free Report has outperformed the market over the past 20 years by 4.74% on an annualized ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Diversify Advisory Services LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 16.3% during the ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Congestive Heart Failure Treatment Market Predicted Growth At 4.47% CAGR To 35.5 Billion USD By 2032 Gilead Sciences The Global Congestive Heart Failure Treatment market is witnessing significant ...